Michael Carus, The founder 
and Managing Director of the nova-Institute studied physics and mathematics at the University of Cologne. Carus became a lecturer at the University of Tübingen, on the topics of ecology, nuclear energy, and radioactivity. He worked as a science journalist and 
scientist at the KATALYSE Environmental Institute with a focus on energy, ecology, and renewable resources, and two years in the solar industry. In 1994, he founded the nova-Institute for Ecology and Innovation. © Nova Institute, Cologne

Plastics are magical materials, and they will be even more important in the future than they are today. But they lead to microplastics in the environment, especially noticeable as marine littering. The European Commission is now proposing, among other things, a ban on certain single-use plastic products, including plastic cotton buds, cutlery, plates, straws, drink stirrers, and sticks for balloons, which will all have to be made exclusively from more sustainable materials instead. The Commission’s legislative proposal must then be negotiated with the member states and the European Parliament. And here substantial changes should still be made because so far industry and politics continued to fail in this area.

Dr. Frank Rijsberman at GBS2018. Picture © BIOCOM AG
tk_11_2017_ute_kilger_16x9.jpg

Is cheaper always better when it comes to generics? What about when it comes to innovative medical uses of them?

EB_Spring_2018_SPENNEMANN__Christoph_tg.jpg
2018_waldemar_kuett.jpg

In mid-November, the European Commission tabled the long-awaited review of its Bioeconomy Strategy and Action Plan. European Biotechnology spoke with Waldemar Kütt, Head of Unit Bioeconomy Strategy, about the development the bioeconomy has made since its launch in 2012 by the European Commission and the instruments needed to attract investments, make it circular, and create a stable policy environment for companies and investors.

Paul Jansen, Haselmeier

PharmaPack 2018:?The promises of digitalised medicine don’t stop at injection pens or autoinjectors. One of the early adopters in the field is Swiss Haselmeier AG (Pharmapack: hall 7.1, booth L19). European Biotechnology spoke with Paul E. Jansen, Member of the Board, from Haselmeier’s Boston office about how connected devices could define a new paradigm in therapy compliance and control of chronic diseases, and how they will shape the market.

johnbrennan.jpg

The UN Sustainable Development Goals (SDGs) provide a powerful blueprint for coordinating global efforts to end poverty through economic growth, reducing inequality, and providing better education, health, job opportunities, and environmental protection.

Picture © OPIS

OPIS   Accelerated approval for orphan drugs and the possibility to have market authorisation
after a successful Phase II trial have made research in rare diseases more attractive to sponsors.
However, challenges and uncertainties remain numerous and designing scientifi cally robust,
patient-centered trials requires proper conceptualisation.

© 4SC AG

Unitary Patent:?Ingve Stjerna, plaintiff before the Federal Constitutional Court, argues that the UPC system does not deliver on its promise to make European patents cheaper and more affordable to Small and Medium-sized Enterprises (SMEs). European Biotechnology asked José Pfizer, Head of Intellectual Property at 4SC AG, to address the issue from the perspective of a German SME. 

Sébastien Stoitzner, CEO. © Gensearch

Today, there are greater expectations among healthcare providers for engagement with life sciences companies to be digital. For life sciences companies, there is significant potential to leverage digital technologies to reach more HCPs.